Stoke Therapeutics earnings were -$169.8M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest STOK earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$50.0M, down 13.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, STOK reported annual earnings of -$6.9M, with -92.3% growth.
What were Stoke Therapeutics's earnings last quarter?
On STOK's earnings call on Invalid Date, Stoke Therapeutics (NASDAQ: STOK) reported Q1 2026 earnings per share (EPS) of -$0.79, up 140.51% year over year. Total STOK earnings for the quarter were -$50.00 million. In the same quarter last year, Stoke Therapeutics's earnings per share (EPS) was $1.95.
As of the last Stoke Therapeutics earnings report, Stoke Therapeutics is currently losing money. Stoke Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$169.77 million, a 437.7% decrease year over year.
What was STOK's earnings growth in the past year?
As of Stoke Therapeutics's earnings date in Invalid Date, Stoke Therapeutics's earnings has grown year over year. STOK earnings in the past year totalled -$169.77 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.